Altimmune is a late-stage clinical biopharmaceutical company focused on serious liver disease. The Company’s lead candidate, pemvidutide*, is a novel dual-action therapy targeting both glucagon and GLP-1 receptors in development for metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). Designed to address both the cause and the consequence of serious liver disease, pemvidutide pairs direct liver effects through glucagon receptor activity with the metabolic benefits of GLP-1 activity. Pemvidutide has received Fast Track and Breakthrough Therapy Designations from the U.S. Food and Drug Administration for MASH and Fast Track Designation for AUD.
ABOUT US
Executive Committee
Altimmune is guided by a leadership team with the vision and depth to evolve the Company to a late-stage clinical company developing pemvidutide to treat serious liver disease. The team brings together deep, complementary industry expertise across global drug development, regulatory approvals, commercialization, and business development to establish a strategic advantage that is purpose-built to support the company’s growth.
President, Chief Executive Officer and Chairman Of The Board
Chief Commercial Officer
Chief Financial Officer
Chief Medical Officer
Chief Scientific Officer
Chief Legal Officer
Vice President, Head of Human Resources
Board of Directors
President, Chief Executive Officer and Chairman Of The Board
Director
Director
Director
Director
Director
Director
Director
Scientific Advisory Boards
MASH
Chief Academic Officer
Summit Clinical Research
Director of Research
Clinical Research Institute of Ohio (CRIOH)
Director of the Steatotic Liver Program
North Shore Gastroenterology
Summit Clinical Research
Director of Research
Clinical Research Institute of Ohio (CRIOH)
Director of the Steatotic Liver Program
North Shore Gastroenterology
David W Crabb Professor of Medicine
Adjunct Professor, Anatomy, Cell Biology and Physiology
Director, Terance Kahn Liver Disease Research Program
Indiana University School of Medicine
Adjunct Professor, Anatomy, Cell Biology and Physiology
Director, Terance Kahn Liver Disease Research Program
Indiana University School of Medicine
Professor of Medicine (with tenure)
Chief, Division of Gastroenterology and Hepatology
Department of Medicine
Director of Hepatology
Director, Liver Epidemiology Training Program
Founding Director, MASLD Research Center
University of California at San Diego
Chief, Division of Gastroenterology and Hepatology
Department of Medicine
Director of Hepatology
Director, Liver Epidemiology Training Program
Founding Director, MASLD Research Center
University of California at San Diego
Alcohol Use Disorder (AUD)
Associate Professor of Medicine Jacobs School of Medicine University at Buffalo Medical Director, Hepatology Erie County Medical Center
Professor Emeritus, Department of Neuroscience, The Scripps Research Institute, La Jolla, CA Adjunct Professor in Psychiatry, the University of California – San Diego
Professor and Vice Dean for Research Lead Investigator, Analytics and PsychoPharmacology Laboratory (APPL) Director, Program of Excellence in Addiction Research
Alcohol-Associated Liver Disease (ALD)
David W Crabb Professor of Medicine
Adjunct Professor, Anatomy, Cell Biology and Physiology
Director, Terance Kahn Liver Disease Research Program
Indiana University School of Medicine
Adjunct Professor, Anatomy, Cell Biology and Physiology
Director, Terance Kahn Liver Disease Research Program
Indiana University School of Medicine
Director, Alcohol-associated Liver Disease Program (ADAPT)
Associate Professor of Medicine and affiliation is University of Southern California
Professor of Medicine (with tenure)
Chief, Division of Gastroenterology and Hepatology
Department of Medicine
Director of Hepatology
Director, Liver Epidemiology Training Program
Founding Director, MASLD Research Center
University of California at San Diego
Chief, Division of Gastroenterology and Hepatology
Department of Medicine
Director of Hepatology
Director, Liver Epidemiology Training Program
Founding Director, MASLD Research Center
University of California at San Diego
Professor of Medicine and Pharmacology & Toxicology
Director
Department of Internal Medicine II
Saarland University Medical Center
Department of Internal Medicine II
Saarland University Medical Center
Partnerships
Great science requires coordinated effort, and we believe that the next generation of medicines for serious liver disease will be built through bold collaboration as a catalyst for innovation. To pursue this vision, we seek out strategic partners who share our urgency and our conviction that the right partnership can help turn scientific breakthroughs into treatments more quickly, to serve patients who cannot wait. We are always open to building strategic alliances that expand what is scientifically and commercially possible.
For partnership opportunities contact:
*Pemvidutide is investigational and has not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority. Safety and efficacy have not been established. There is no guarantee that it will successfully complete clinical development or receive regulatory approval.
